MA43183A - Agent thérapeutique antitumoral contenant une composition liposomale à base de gemcitabine et kit associé - Google Patents
Agent thérapeutique antitumoral contenant une composition liposomale à base de gemcitabine et kit associéInfo
- Publication number
- MA43183A MA43183A MA043183A MA43183A MA43183A MA 43183 A MA43183 A MA 43183A MA 043183 A MA043183 A MA 043183A MA 43183 A MA43183 A MA 43183A MA 43183 A MA43183 A MA 43183A
- Authority
- MA
- Morocco
- Prior art keywords
- gemcitabine
- therapeutic agent
- agent containing
- composition based
- liposomal composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015215768 | 2015-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43183A true MA43183A (fr) | 2018-09-12 |
Family
ID=58662534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043183A MA43183A (fr) | 2015-11-02 | 2016-11-01 | Agent thérapeutique antitumoral contenant une composition liposomale à base de gemcitabine et kit associé |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11166913B2 (fr) |
| EP (1) | EP3372232B1 (fr) |
| JP (1) | JP6602886B2 (fr) |
| KR (1) | KR102084340B1 (fr) |
| CN (3) | CN108348538B (fr) |
| DK (1) | DK3372232T3 (fr) |
| ES (1) | ES2869283T3 (fr) |
| MA (1) | MA43183A (fr) |
| PL (1) | PL3372232T3 (fr) |
| RU (3) | RU2768178C2 (fr) |
| WO (1) | WO2017078008A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3138555B1 (fr) | 2014-04-30 | 2020-10-28 | FUJIFILM Corporation | Composition liposomale et procédé de production associé |
| CN108348538B (zh) | 2015-11-02 | 2021-06-22 | 富士胶片株式会社 | 包含吉西他滨脂质体组合物的肿瘤治疗药及试剂盒 |
| EP3603620A4 (fr) | 2017-03-31 | 2020-03-25 | FUJIFILM Corporation | Composition de liposome et composition pharmaceutique |
| EP3811931A4 (fr) * | 2018-06-20 | 2021-08-04 | FUJIFILM Corporation | Médicament combiné contenant une composition de liposome encapsulant un médicament et un inhibiteur de point de contrôle immunitaire |
| CA3104084C (fr) * | 2018-06-20 | 2023-08-01 | Fujifilm Corporation | Medicament combine comprenant une composition de liposome encapsulee par gemcitabine et un blocage de point de controle immunitaire |
| JP7057434B2 (ja) * | 2018-10-01 | 2022-04-19 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物およびプラチナ製剤を含む組合せ医薬 |
| CN112898277B (zh) * | 2019-11-19 | 2022-04-22 | 扬子江药业集团有限公司 | 一种阿法替尼中间体的制备方法 |
| CN111035616B (zh) * | 2019-12-30 | 2022-03-22 | 上海景峰制药有限公司 | 一种吉西他滨脂质体及其制备方法和应用 |
| JP2021181426A (ja) * | 2020-04-03 | 2021-11-25 | 富士フイルム株式会社 | 抗腫瘍剤 |
| WO2023179423A1 (fr) * | 2022-03-25 | 2023-09-28 | 四川科伦药物研究院有限公司 | Composition pharmaceutique de liposome de gemcitabine, son procédé de préparation et son utilisation |
| WO2023186923A1 (fr) | 2022-03-30 | 2023-10-05 | Meta Materials Inc. | Système implanté d'administration d'agent |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
| AU2003268087A1 (en) | 2002-08-23 | 2004-03-11 | Ian Ma | Liposomal gemcitabine compositions for better drug delivery |
| EP1643971A2 (fr) * | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Formulations liposomales combinees |
| JPWO2005021012A1 (ja) * | 2003-08-29 | 2006-10-26 | テルモ株式会社 | ゲムシタビン封入薬剤担体 |
| KR101462825B1 (ko) | 2004-05-03 | 2014-11-21 | 헤르메스 바이오사이언스, 인코포레이티드 | 약물 전달에 유용한 리포좀 |
| US20070014845A1 (en) * | 2005-07-01 | 2007-01-18 | Yuanpeng Zhang | Liposomal delivery vehicle for hydrophobic drugs |
| WO2007067784A2 (fr) * | 2005-12-08 | 2007-06-14 | Wyeth | Compositions liposomales |
| US8119156B2 (en) * | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| CN101209243B (zh) | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术（石家庄）有限公司 | 一种脂质体药物及其制备方法 |
| CN100496609C (zh) * | 2006-12-30 | 2009-06-10 | 上海艾力斯医药科技有限公司 | 一种稳定的脂质体组合物 |
| EP2171135A2 (fr) * | 2007-06-22 | 2010-04-07 | Innovative Surface Technologies, Inc. | Nanofibres sensibles à des stimuli |
| US20100239652A1 (en) * | 2007-09-28 | 2010-09-23 | Universitatsspital Basel | Immunoliposomes for treatment of cancer |
| US8079820B2 (en) * | 2008-12-18 | 2011-12-20 | General Electric Company | Blade module, a modular rotor blade and a method for assembling a modular rotor blade |
| EP2394640A1 (fr) | 2010-05-21 | 2011-12-14 | MediGene AG | Formulations liposomales améliorées de composés lipophiles |
| RU2571077C2 (ru) * | 2011-03-25 | 2015-12-20 | Терумо Кабусики Кайся | Липосомальная композиция длительного действия с контролируемым высвобождением и способ ее получения |
| US8987224B2 (en) * | 2011-08-05 | 2015-03-24 | Baylor College Of Medicine | MicroRNA-198 as a tumor suppressor in pancreatic cancer |
| MX360391B (es) * | 2011-10-31 | 2018-10-31 | Mallinckrodt Llc | Composiciones liposomales combinadas para terapia contra el cancer. |
| EP2604253A1 (fr) * | 2011-12-13 | 2013-06-19 | Otto Glatter | Émulsion eau dans l'huile et leurs procédés de préparation |
| ES2673093T3 (es) * | 2012-04-04 | 2018-06-19 | Halozyme, Inc. | Terapia combinada con hialuronidasa y un taxano dirigido a un tumor |
| CN102784107B (zh) * | 2012-05-17 | 2015-04-22 | 江苏豪森药业股份有限公司 | 一种吉西他滨或其盐脂质体及其制备方法和用途 |
| AU2013360302C1 (en) * | 2012-12-12 | 2019-01-24 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of cancer |
| CA2936345A1 (fr) | 2013-01-14 | 2014-07-17 | Chemo-Enhanced Llc | Compositions et procedes pour traiter le cancer |
| WO2014138278A1 (fr) | 2013-03-05 | 2014-09-12 | The Regents Of The University Of California | Nanoparticules de silice mésoporeuse revêtues par une bi-couche lipidique ayant une capacité élevée de charge pour un ou plusieurs agents anticancer |
| WO2015166987A1 (fr) * | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | Composition liposomale et procédé de production associé |
| WO2015166985A1 (fr) * | 2014-04-30 | 2015-11-05 | 富士フイルム株式会社 | Composition liposomale et procédé de production associé |
| CN108348538B (zh) | 2015-11-02 | 2021-06-22 | 富士胶片株式会社 | 包含吉西他滨脂质体组合物的肿瘤治疗药及试剂盒 |
| WO2017192863A1 (fr) * | 2016-05-04 | 2017-11-09 | L.E.A.F. Holdings Group Llc | Compositions de gemcitabine liposomale ciblée et procédés correspondants |
-
2016
- 2016-11-01 CN CN201680064060.7A patent/CN108348538B/zh active Active
- 2016-11-01 DK DK16862068.0T patent/DK3372232T3/da active
- 2016-11-01 ES ES16862068T patent/ES2869283T3/es active Active
- 2016-11-01 WO PCT/JP2016/082415 patent/WO2017078008A1/fr active Application Filing
- 2016-11-01 RU RU2020137385A patent/RU2768178C2/ru active
- 2016-11-01 PL PL16862068T patent/PL3372232T3/pl unknown
- 2016-11-01 KR KR1020187012568A patent/KR102084340B1/ko active IP Right Grant
- 2016-11-01 CN CN202010466892.XA patent/CN111632030B/zh active Active
- 2016-11-01 CN CN202010466486.3A patent/CN111437259A/zh active Pending
- 2016-11-01 RU RU2020137384A patent/RU2761620C2/ru active
- 2016-11-01 RU RU2018119680A patent/RU2738365C2/ru active
- 2016-11-01 JP JP2017548769A patent/JP6602886B2/ja active Active
- 2016-11-01 EP EP16862068.0A patent/EP3372232B1/fr active Active
- 2016-11-01 MA MA043183A patent/MA43183A/fr unknown
-
2018
- 2018-05-01 US US15/967,970 patent/US11166913B2/en active Active
-
2020
- 2020-03-03 US US16/808,004 patent/US11166914B2/en active Active
-
2021
- 2021-02-25 US US17/184,928 patent/US20210275453A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN111632030A (zh) | 2020-09-08 |
| US11166913B2 (en) | 2021-11-09 |
| RU2761620C2 (ru) | 2021-12-13 |
| RU2018119680A (ru) | 2019-12-05 |
| RU2020137385A (ru) | 2020-12-03 |
| CN111437259A (zh) | 2020-07-24 |
| KR20180054873A (ko) | 2018-05-24 |
| ES2869283T3 (es) | 2021-10-25 |
| DK3372232T3 (da) | 2021-06-07 |
| RU2020137385A3 (fr) | 2021-03-31 |
| US20210275453A1 (en) | 2021-09-09 |
| WO2017078008A1 (fr) | 2017-05-11 |
| JPWO2017078008A1 (ja) | 2018-08-09 |
| EP3372232A4 (fr) | 2018-11-14 |
| US11166914B2 (en) | 2021-11-09 |
| CN108348538B (zh) | 2021-06-22 |
| CN108348538A (zh) | 2018-07-31 |
| EP3372232B1 (fr) | 2021-04-14 |
| RU2020137384A3 (fr) | 2021-03-31 |
| JP6602886B2 (ja) | 2019-11-06 |
| PL3372232T3 (pl) | 2021-09-27 |
| EP3372232A1 (fr) | 2018-09-12 |
| US20200197305A1 (en) | 2020-06-25 |
| RU2020137384A (ru) | 2020-12-03 |
| RU2018119680A3 (fr) | 2019-12-05 |
| RU2768178C2 (ru) | 2022-03-23 |
| CN111632030B (zh) | 2023-01-17 |
| KR102084340B1 (ko) | 2020-03-03 |
| US20180243214A1 (en) | 2018-08-30 |
| RU2738365C2 (ru) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43183A (fr) | Agent thérapeutique antitumoral contenant une composition liposomale à base de gemcitabine et kit associé | |
| DK3706796T3 (da) | Eksosomerer som RNA terapeutikske midler | |
| MA43377A (fr) | Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| GB201715898D0 (en) | Proactive virtual assistant | |
| MA40764A (fr) | Agent thérapeutique induisant une cytotoxicité | |
| GEP20217239B (en) | Pharmaceutical composition | |
| ES2841649T5 (es) | Composición farmacéutica | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| PT3513809T (pt) | Composição medicinal compreendendo tivozanib | |
| DK3386523T3 (da) | Bifidobacterium longum til behandling af fedme og associerede metabolske sygdomme | |
| MA51228A (fr) | Agent antitumoral | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| FR23C1037I1 (fr) | Compositions à base de mycoplasma bovis | |
| DK3275457T3 (da) | Farmaceutisk sammensætning omfattende silybin og pu'er-te-essens | |
| BR112016030507A2 (pt) | Compostos relacionados à vitamina d, composição farmacêutica, e kit | |
| DK3154542T3 (da) | Fremgangsmåder og sammensætninger rettet mod depressionsfølelse | |
| DK3512544T3 (da) | Peptidforbindelser og terapeutiske anvendelser deraf | |
| DK3432887T3 (da) | Anti-tuberkulosemiddel | |
| DK3302483T3 (da) | Farmaceutiske sammensætninger og anvendelse deraf | |
| ITUB20156000A1 (it) | Composizione nematocida e suo utilizzo | |
| DK3359185T3 (da) | Antitumoral sammensætning | |
| DK3373976T3 (da) | Topiske formuleringer og anvendelser deraf | |
| LU92630B1 (fr) | Compositions contenant de la curcumine à biodisponibilité améliorée | |
| IL260569B (en) | Radiolabeled erlotinib analogs and uses thereof |